Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

NCT06050694 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

DRUG: glofitamab

Sponsor

University Health Network, Toronto